OncoC4, Inc.
OncoC4 is a late-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer and neurological diseases. With a focus on first-in-class and best-in-class medicines, the company leverages innate and adaptive immune checkpoints to target hard-to-treat cancers and Alzheimer's disease. Their pipeline includes advanced clinical candidates, preclinical assets, and partnered programs, aiming to provide safer, more effective, and durable cancer treatments.
Industries
Nr. of Employees
small (1-50)
OncoC4, Inc.
Patents
Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
US-12129299-B2
View DetailsChimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
US-11629188-B2
View DetailsChimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
US-10618960-B2
View Details
Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
US-12129299-B2
View DetailsChimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
US-11629188-B2
View DetailsChimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
US-10618960-B2
View DetailsProducts
PD‑1/VEGF bispecific antibody (clinical-stage)
Development of a head‑and‑tail configured bispecific antibody targeting PD‑1 and VEGF designed to concentrate activity in the tumor microenvironment and reduce systemic angiogenesis toxicity; advanced through IND enabling and early clinical development.
pH‑sensitive anti‑CTLA‑4 antibody (next‑generation, clinical‑stage)
A pH‑sensitive monoclonal antibody designed to preserve CTLA‑4 recycling and selectively deplete tumor‑infiltrating regulatory T cells, with clinical evaluation as monotherapy and in combinations.
SIGLEC10 antagonist antibody (first‑in‑class, clinical‑stage)
A humanized antagonist antibody targeting SIGLEC10 to block an innate immune checkpoint, enhance phagocytosis and rejuvenate NK, macrophage and T‑cell activity in the tumor microenvironment; progressed to Phase 1 clinical testing.
Cancer‑specific CD24 antibody platform
Discovery and development of antibodies targeting a cancer‑specific neo‑epitope of CD24 to enable selective targeting across solid and hematologic malignancies and enable multiple modalities (mAb, bispecific, ADC, CAR‑T).
CAR T‑cell therapy targeting CD24 (preclinical/IND enabling)
Development of CAR T‑cell therapies directed at the CD24 neo‑epitope for solid and hematologic malignancies with planned investigator‑initiated clinical evaluation.
Bispecific antibody for hematologic malignancies (preclinical)
Preclinical development of bispecific antibody formats aimed at hematologic cancers, currently in IND‑enabling stages.
PD‑1/VEGF bispecific antibody (clinical-stage)
Development of a head‑and‑tail configured bispecific antibody targeting PD‑1 and VEGF designed to concentrate activity in the tumor microenvironment and reduce systemic angiogenesis toxicity; advanced through IND enabling and early clinical development.
pH‑sensitive anti‑CTLA‑4 antibody (next‑generation, clinical‑stage)
A pH‑sensitive monoclonal antibody designed to preserve CTLA‑4 recycling and selectively deplete tumor‑infiltrating regulatory T cells, with clinical evaluation as monotherapy and in combinations.
SIGLEC10 antagonist antibody (first‑in‑class, clinical‑stage)
A humanized antagonist antibody targeting SIGLEC10 to block an innate immune checkpoint, enhance phagocytosis and rejuvenate NK, macrophage and T‑cell activity in the tumor microenvironment; progressed to Phase 1 clinical testing.
Cancer‑specific CD24 antibody platform
Discovery and development of antibodies targeting a cancer‑specific neo‑epitope of CD24 to enable selective targeting across solid and hematologic malignancies and enable multiple modalities (mAb, bispecific, ADC, CAR‑T).
CAR T‑cell therapy targeting CD24 (preclinical/IND enabling)
Development of CAR T‑cell therapies directed at the CD24 neo‑epitope for solid and hematologic malignancies with planned investigator‑initiated clinical evaluation.
Bispecific antibody for hematologic malignancies (preclinical)
Preclinical development of bispecific antibody formats aimed at hematologic cancers, currently in IND‑enabling stages.
Services
End‑to‑end clinical operations including protocol implementation, site selection, site monitoring (onsite and remote), investigator communication, and trial close‑out activities.
Set up and maintain CTMS and eTMF for regulatory document management, quality control checks, and preparation for audits/inspections.
Preparation of IND packages and interactions with regulatory authorities to obtain study‑ready notifications and enable clinical initiation.
In‑house clinical manufacturing capabilities to support R&D and clinical supply operations, including CMC activities for biologics.
End‑to‑end clinical operations including protocol implementation, site selection, site monitoring (onsite and remote), investigator communication, and trial close‑out activities.
Set up and maintain CTMS and eTMF for regulatory document management, quality control checks, and preparation for audits/inspections.
Preparation of IND packages and interactions with regulatory authorities to obtain study‑ready notifications and enable clinical initiation.
In‑house clinical manufacturing capabilities to support R&D and clinical supply operations, including CMC activities for biologics.
Expertise Areas
- Clinical trial management
- Immuno-oncology
- Antibody engineering
- Biologics development and CMC
Key Technologies
- Monoclonal antibody engineering
- Bispecific antibody design
- Fc engineering (effector modulation / silencing)
- pH-sensitive antibody design
News & Updates
Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody. Initial Phase 1 data and other updates will be discussed.
FDA has cleared an IND for AI-081, a bispecific antibody targeting PD-1 and VEGF, with plans to initiate a Phase 1/2 trial in early 2025.
Coverage of OncoC4's merger with AcroImmune and other news highlights.
OncoC4 merges with AcroImmune to expand pipeline and establish manufacturing capabilities, including IND-ready AI-081 and next-generation siglec assets.
FDA has cleared the IND for AI-081, a bispecific antibody targeting PD-1 and VEGF, with plans to start Phase 1/2 trials in 2025.
Dr. Yang Liu was acknowledged for his leadership and innovative approach in the biopharmaceutical industry.
Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody. Initial Phase 1 data and other updates will be discussed.
FDA has cleared an IND for AI-081, a bispecific antibody targeting PD-1 and VEGF, with plans to initiate a Phase 1/2 trial in early 2025.
Coverage of OncoC4's merger with AcroImmune and other news highlights.
OncoC4 merges with AcroImmune to expand pipeline and establish manufacturing capabilities, including IND-ready AI-081 and next-generation siglec assets.
FDA has cleared the IND for AI-081, a bispecific antibody targeting PD-1 and VEGF, with plans to start Phase 1/2 trials in 2025.
Dr. Yang Liu was acknowledged for his leadership and innovative approach in the biopharmaceutical industry.